LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 684

Search options

  1. Article ; Online: Gavin Giovannoni on why time matters in multiple sclerosis.

    Giovannoni, Gavin

    Neurodegenerative disease management

    2016  Volume 6, Issue 2, Page(s) 77–79

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Clinical Trials, Phase III as Topic/methods ; Humans ; Immunosuppressive Agents/therapeutic use ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/immunology ; Research Personnel/trends ; Time Factors
    Chemical Substances Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; ocrelizumab (A10SJL62JY)
    Language English
    Publishing date 2016-04
    Publishing country England
    Document type Interview
    ISSN 1758-2032
    ISSN (online) 1758-2032
    DOI 10.2217/nmt.16.3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Targeting Epstein-Barr virus in multiple sclerosis: when and how?

    Giovannoni, Gavin

    Current opinion in neurology

    2024  Volume 37, Issue 3, Page(s) 228–236

    Abstract: Purpose of review: Epidemiological evidence implicates Epstein-Barr virus (EBV) as the cause of multiple sclerosis (MS). However, its biological role in the pathogenesis of MS is uncertain. The article provides an overview of the role of EBV in the ... ...

    Abstract Purpose of review: Epidemiological evidence implicates Epstein-Barr virus (EBV) as the cause of multiple sclerosis (MS). However, its biological role in the pathogenesis of MS is uncertain. The article provides an overview of the role of EBV in the pathogenesis of MS and makes a case for targeting EBV as a treatment strategy for MS.
    Recent findings: EBV potentially triggers autoimmunity via molecular mimicry or immune dysregulation. Another hypothesis, supported by immunological and virological data, indicates that active EBV infection via latent-lytic infection cycling within the central nervous system or periphery drives MS disease activity. This supports testing small molecule anti-EBV agents targeting both latent and lytic infection, central nervous system-penetrant B-cell therapies and EBV-targeted immunotherapies in MS. Immunotherapies may include EBV-specific cytotoxic or chimeric antigen receptors T-cells, therapeutic EBV vaccines and immune reconstitution therapies to boost endogenous EBV-targeted cytotoxic T-cell responses.
    Summary: EBV is the probable cause of MS and is likely to be driving MS disease activity via latent-lytic infection cycling. There is evidence that all licensed MS disease-modifying therapies target EBV, and there is a compelling case for testing other anti-EBV strategies as potential treatments for MS.
    MeSH term(s) Humans ; Multiple Sclerosis/immunology ; Multiple Sclerosis/therapy ; Epstein-Barr Virus Infections/immunology ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Infections/therapy ; Herpesvirus 4, Human/immunology ; Immunotherapy/methods
    Language English
    Publishing date 2024-03-21
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 1182686-1
    ISSN 1473-6551 ; 1350-7540
    ISSN (online) 1473-6551
    ISSN 1350-7540
    DOI 10.1097/WCO.0000000000001266
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2524: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.

    Giovannoni, Gavin

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2023  Volume 29, Issue 9, Page(s) 1068–1069

    MeSH term(s) Humans ; Quality of Life ; Immunosuppressive Agents ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis/drug therapy
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2023-07-25
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585231182702
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model.

    Giovannoni, Gavin

    Multiple sclerosis and related disorders

    2022  Volume 68, Page(s) 104222

    MeSH term(s) Humans ; Multiple Sclerosis/therapy ; Models, Theoretical
    Language English
    Publishing date 2022-10-07
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2022.104222
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?

    Giovannoni, Gavin

    Multiple sclerosis and related disorders

    2022  Volume 63, Page(s) 103803

    MeSH term(s) COVID-19 ; COVID-19 Vaccines ; Humans ; Multiple Sclerosis/drug therapy ; SARS-CoV-2
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2022-04-11
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2022.103803
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.

    Giovannoni, Gavin

    Multiple sclerosis and related disorders

    2020  Volume 41, Page(s) 102135

    MeSH term(s) Antibodies, Monoclonal, Humanized ; Antigens, CD20 ; Betacoronavirus ; COVID-19 ; Coronavirus Infections ; Humans ; Immunosuppression ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antigens, CD20 ; ocrelizumab (A10SJL62JY)
    Keywords covid19
    Language English
    Publishing date 2020-04-18
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2020.102135
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Do we have equipoise when it comes to how we treat active multiple sclerosis?

    Giovannoni, Gavin

    The Lancet. Neurology

    2019  Volume 18, Issue 10, Page(s) 909–911

    MeSH term(s) Humans ; Multiple Sclerosis ; Recurrence
    Language English
    Publishing date 2019-07-30
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2079704-7
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(19)30227-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Survival: the ultimate long-term outcome in multiple sclerosis.

    Giovannoni, Gavin

    Brain : a journal of neurology

    2019  Volume 142, Issue 5, Page(s) 1166–1167

    MeSH term(s) Humans ; Interferon-beta ; Multiple Sclerosis
    Chemical Substances Interferon-beta (77238-31-4)
    Language English
    Publishing date 2019-04-19
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 80072-7
    ISSN 1460-2156 ; 0006-8950
    ISSN (online) 1460-2156
    ISSN 0006-8950
    DOI 10.1093/brain/awz101
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.26: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: A place for biosimilars in the changing multiple sclerosis treatment landscape.

    Greenberg, Benjamin / Giovannoni, Gavin

    Multiple sclerosis and related disorders

    2023  Volume 77, Page(s) 104841

    Abstract: Background: The treatment paradigm for multiple sclerosis (MS), particularly relapsing-remitting MS, is heavily reliant on biologic disease-modifying therapies (DMTs). However, the current cost of treatment acts as a significant barrier to access for ... ...

    Abstract Background: The treatment paradigm for multiple sclerosis (MS), particularly relapsing-remitting MS, is heavily reliant on biologic disease-modifying therapies (DMTs). However, the current cost of treatment acts as a significant barrier to access for patients. Over the next few years exclusivity periods for key biologic medicines used in MS are likely to end, opening the door for biosimilar medicines to enter the market.
    Methods: In this review, we discuss what biosimilar medicines are, and how the existing experience with biosimilar medicines across multiple therapy areas can inform the assimilation of biosimilar medicines into the MS treatment landscape in Europe and the US.
    Results: There is currently a lack of knowledge and awareness around the distinctions and similarities between small molecules, non-biological complex drugs, and biological medicines, as well as the different categories of follow-on successor medicines. These include biosimilar medicines that offer a matching efficacy and safety profile to the reference biologic. Understanding and recognition of the stringency of the approval pathways required for drug categories such as biosimilars are key in building confidence in treatment outcomes. For example, biosimilar medicines are sometimes perceived only as 'copies' of their reference biologic despite undergoing an extensive approval process requiring that no clinically meaningful differences are observed between the biosimilar medicine and the reference medicine. For MS, introduction of biosimilar medicines in the future will enable more people with MS to receive effective treatment, and also expand access to biologic DMTs in MS. Experiences from the use of biosimilars in multiple therapy areas have shown us that this can result in cost-saving benefits for a healthcare system. Introduction of biosimilar medicines in other therapy areas has also demonstrated the importance of appropriate, accurate education and information for their successful integration into clinical practice.
    Conclusion: In order to realize optimized treatment outcomes in MS in coming years and to find the appropriate place for biosimilar medicines in the changing MS landscape, it is essential that clinicians and people with MS understand the fundamentals of biosimilars, their potential benefits and consistency of treatment provided by a biosimilar medicine, given the matching efficacy and safety profile to its reference medicine. As evidenced in other therapy areas, biosimilar medicines may reduce key barriers to access by providing a cost-effective alternative to the MS treatment arsenal, while providing the same treatment outcomes as reference biologics.
    MeSH term(s) Humans ; Biosimilar Pharmaceuticals/therapeutic use ; Multiple Sclerosis/drug therapy ; Treatment Outcome ; Europe
    Chemical Substances Biosimilar Pharmaceuticals
    Language English
    Publishing date 2023-06-19
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2023.104841
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Open access publishing and the future of scientific communication.

    Hawkes, Christopher H / Giovannoni, Gavin / Lechner-Scott, Jeanette / Levy, Michael / Yeh, Ann

    Multiple sclerosis and related disorders

    2024  Volume 86, Page(s) 105625

    Language English
    Publishing date 2024-04-15
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2024.105625
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top